Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2003 1
2005 2
2006 1
2009 1
2011 1
2012 1
2013 5
2014 2
2015 1
2016 1
2018 1
2019 1
2020 2
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, Malinge L, Sémiond D, van de Velde H, Yong K. Dimopoulos MA, et al. Among authors: semiond d. Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23. Leukemia. 2021. PMID: 32444867 Free PMC article. Clinical Trial.
Preclinical profile of cabazitaxel.
Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Vrignaud P, et al. Among authors: semiond d. Drug Des Devel Ther. 2014 Oct 13;8:1851-67. doi: 10.2147/DDDT.S64940. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25378905 Free PMC article. Review.
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: semiond d. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. Mikhael J, et al. Among authors: semiond d. Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4. Blood Cancer J. 2021. PMID: 33980831 Free PMC article. No abstract available.
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Ugolini A, Kenigsberg M, Rak A, Vallée F, Houtmann J, Lowinski M, Capdevila C, Khider J, Albert E, Martinet N, Nemecek C, Grapinet S, Bacqué E, Roesner M, Delaisi C, Calvet L, Bonche F, Semiond D, Egile C, Goulaouic H, Schio L. Ugolini A, et al. Among authors: semiond d. J Med Chem. 2016 Aug 11;59(15):7066-74. doi: 10.1021/acs.jmedchem.6b00280. Epub 2016 Jul 13. J Med Chem. 2016. PMID: 27355974
23 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page